Ensysce Biosciences Stock (NASDAQ:ENSC), Trade Ideas

Ensysce Biosciences

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

AMSC

CONNEXA SPORTS TECH INC by Connexa Sports Technologies Inc.

CNXA

DCGO

ENSC

EVAX

EVTV

EXTR

GNPX

GOOG

GOOGL

ALPS ETF Trusthen & Steers Global Realty Majors ETF

HTLF

KUKE

MARK

MINM

MKTX

NVVE

NYCB

NYXH

OBLG

PARA

PLUG

POWL

REVB

RVSN

SLDB

SNPX

TRIB

TSVT

VXRT

ZJYL

Shares of Advanced Micro Devices, Inc. (NASDAQ: AMD) shares declined 3.8% to $165.49 following fourth-quarter results.

AMD reported fourth-quarter non-GAAP earnings per share of 77 cents per share on revenue of $6.17 billion.

AMD shares dipped 3.8% to $165.49 on Wednesday.

Why AMD Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

ANVS

CRIS

DWAC

EVER

GETR

GPAK

GYRE

HRTX

KURA

LCID

MMAT

NFLX

PRPL

RDHL

SAVE

SBEV

SIDU

SMMT

SPRC

SRAD

SWIN

VSME

Shares of BlackBerry Limited (NYSE: BB) fell sharply during Wednesday’s session after the company announced a proposed private offering of $160 million of convertible senior notes.

BlackBerry shares tumbled 17.2% to $2.9387 on Wednesday.

Why BlackBerry Shares Are Trading Lower By Over 17%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Pre-Market Outlook

CVKD

ETAO

FAZE

GREE

SNOA

VTVT

ZCAR

Shares of  Netflix, Inc. (NASDAQ: NFLX) shares rose sharply in today’s pre-market trading as the company reported better-than-expected sal

Why Netflix Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket

Ensysce Biosciences Inc

Ensysce Biosciences Inc Warrants (05/12/2019)

WIIM

TFIN

Triumph Financial shares are trading lower after the company reported worse-than-expected Q1 financial results.

Earnings

LRLCY

L'Oreal Q1 Sales €11.24 Billion, +9.4% Like-For-Like; Q1 Sales In North America +12.3% Like-For-Like At €3.02 Billion

<p>This was a big week for connected events. The increase in the CPI was a surprise to the disinflation crowd that&rsquo;s been screaming for lower interest rates for almost two years. Higher CPI leads to higher for longer interest rates which pushes up the dollar against the yen. That&rsquo;s about to force the Bank of Japan to act by selling US Treasuries increasing the already stratospheric borrowing cost of the US government. On the commodity side of things, the White House decided to pass on replenishing the Strategic Petroleum Reserve as oil prices now approach $90 a barrel after passing on replenishing the SPR when oil was below $70. Guest, Tracy Shuchart @chigrl explains that worldwide oil inventories are falling even as the Saudis and Russians maintain extended production cuts. Check her out on this week&rsquo;s <a href="https://www.youtube.com/@DeepKnowledgeInvesting">video version of the 5 Things</a> out Monday night. Finally, we highlight some of the ways commercial real estate landlords are legally lying. If it seems complicated, don&rsquo;t worry: We&rsquo;ll explain&hellip;</p>
<p>This week, we&rsquo;ll address the following topics:</p>
<ul>
<li>
<p>The CPI comes in high. The disinflation story is crumbling. Am I going to say &ldquo;the line&rdquo;? See below to find out.</p>
</li>
<li>
<p>The Bank of Japan is being forced to act. That&rsquo;s going to have negative consequences for the US. We&rsquo;ll explain why.</p>
</li>
<li>
<p>The Commodity Trader in Chief missed the big trade and plans to execute the &ldquo;fingers crossed&rdquo; strategy going into the fall hurricane season.</p>
</li>
<li>
<p>It&rsquo;s not just domestic oil supply. Tracy Shuchart @chigrl explains that global oil inventories are declining as well. Another guest thing &ndash; check out Tracy on this week&rsquo;s <a href="https://www.youtube.com/@DeepKnowledgeInvesting">video edition</a>.</p>
</li>
<li>
<p>Commercial real estate gets worse. Office landlords are finding creative ways to tell the &ldquo;truth&rdquo;.</p>
</li>
</ul>
<p>I want to offer a round of applause for last week&rsquo;s guest, <a href="https://deepknowledgeinvesting.com/board-of-advisors/">DKI Board Member</a>, <a href="https://deepknowledgeinvesting.com/howard-freedland-1/">Howard Freedland</a>, who gave a well-reasoned explanation of the effect of the new broker commission rules on pricing for housing and commercial real estate. Another round of applause for DKI Intern, Andrew Brown, who prepares the graphs for the 5 Things, pitches several of the Things we use each week, edits and posts the video, and was an <a href="https://www.youtube.com/watch?v=2iZq9Cd2jvg">on-air guest explaining</a> the errors in recent Congressional Budget Office projections. Pretty impressive for a college &ldquo;kid&rdquo;. Thanks also to Flying V CEO, <a href="https://twitter.com/robbfahrion?lang=en">Robb Fahrion</a>, who shows up well-prepared each week to host the 5 Things.</p>
<p>Ready for a new week of more expensive information? Let&rsquo;s dive in:</p>
<ul>
<li>
<p><strong>The CPI Comes in High and is Still Understated:</strong></p>
</li>
</ul>
<p>The March Consumer Price Index (CPI) was up 3.5% for the year and 0.4% for the month. That annualizes to 4.9%. This was above last month&rsquo;s 3.2% and expectations of 3.4%. The still-high Core CPI, which excludes food and energy, remained at 3.8%. That&rsquo;s almost double the Fed&rsquo;s 2% target. The energy price declines which fueled last year&rsquo;s disinflation story have reversed as crude and gasoline prices rise. (Disinflation is inflation at a slower rate.) Shelter, a fancy word for housing, continues to rise in price causing some people to start to pay their rent using buy now pay later programs! And DKI continues to express skepticism at any report that claims food inflation was 2.2%. Readers:&nbsp; Is your grocery bill up only 2.2%?</p>
<p><img alt="cpi_-_march_24_1.jpg" src="https://www.benzinga.com/files/images/2024/April/18/cpi_-_march_24_1.jpg" style="height:380px; width:624px" /></p>
<p>Core remains sticky. The CPI is heading back up again.</p>
<p><img alt="real_interest_rates_1.jpg" src="https://www.benzinga.com/files/images/2024/April/18/real_interest_rates_1.jpg" style="height:358px; width:624px" /></p>
<p>The real interest rate is the CPI less the fed funds rate. We&rsquo;re back below 2%.</p>
<p>DKI Takeaway:&nbsp; When the market thought we&rsquo;d have six rate cuts (totaling 1.5%) this year starting in January, DKI said &ldquo;<a href="https://youtu.be/bA-UPrK_x-k?si=go6ct0RXmZbPBGeK&amp;t=15">we find that hard to believe</a>&rdquo;. When the market thought we&rsquo;d see three rate cuts (.75%) this year starting in June, DKI said &ldquo;<a href="https://youtu.be/bA-UPrK_x-k?si=ZVsSuLZfBNZoIlYg&amp;t=21">we don&rsquo;t think so</a>&rdquo;. The current debate is now between zero and two cuts starting in September. This is a blow to political incumbents facing re-election in November who were hoping for fed-fueled stimulus. All of this is the reason DKI subscribers have been making great profits in dollar alternatives and inflation beneficiaries like Bitcoin, gold, and oil/energy. You know the conclusion: &ldquo;higher for longer&rdquo;.</p>
<ul>
<li>
<p><strong>The Bank of Japan is Being Forced to Act:</strong></p>
</li>
</ul>
<p>I started <a href="https://deepknowledgeinvesting.com/japanese-debt-were-taking-a-victory-lap/">speaking and writing</a> about serious problems related to Japan&rsquo;s massive debt in October of 2022. The Bank of Japan (BoJ) had kept their version of the fed funds rate below zero for years, and only recently moved to slightly positive. Those below-market rates led to the yen plummeting from just over 100 to the dollar to the current 153 per dollar. In the US, we don&rsquo;t like to see an inflation rate above 2%. Imagine the buying power of your currency falling by 50% in just a few years. With debt to GDP of over 260%, the BoJ is now stuck. The options are to keep rates where they are, and watch their currency crumble, or raise rates and have to print more yen to pay higher interest expense. There&rsquo;s no way out.</p>
<p><img alt="usd_-_yen.jpg" src="https://www.benzinga.com/files/images/2024/April/18/usd_-_yen.jpg" style="height:368px; width:624px" /></p>
<p>The line going up shows the loss of purchasing power for the yen.</p>
<p>DKI Takeaway:&nbsp; Trillions of dollars have been invested in the &ldquo;carry trade&rdquo; which involves selling low-yielding Japanese Government Bonds and buying higher-yielding US Treasuries. This strategy provided guaranteed profits on the difference in bond yields, but came with the risk that the relative value of the dollar and yen could reverse. With the yen falling to 153 per dollar this week, the BoJ is likely to react by selling holdings of US Treasuries, effectively selling the dollar and buying the yen. When investors start to unwind the carry trade, we&rsquo;ll see enough selling of US Treasuries to lower the price of US government debt increasing the yield. That would increase the already massive interest expense being incurred on our behalf by Washington DC and force more dollar printing. The result of that would be more inflation. We&rsquo;re happy to see more people starting to recognize this problem with more articles in the press and attention on Twitter/X. If you&rsquo;d value knowing these kinds of things a year and a half before they&rsquo;re common knowledge, we invite you to <a href="https://deepknowledgeinvesting.com/subscribe-now/">subscribe</a>.</p>
<ol>
<li>
<p><strong>The Commodity Trader in Chief Missed the Big Trade:</strong></p>
</li>
</ol>
<p>Faced with high inflation and skyrocketing energy prices in 2022, the White House made a huge gamble. They drained the Strategic Petroleum Reserve (SPR) to a 40-year low in order to bring down gas prices ahead of the midterm elections. Without a big hurricane that fall to take oil production offline, the strategy worked. Gas prices fell and the Democrats outperformed expectations in that election. The Administration stated an intention to replenish the SPR when oil fell into the $70s. However, they passed on any meaningful activity when West Texas Intermediate (WTI) crude oil prices fell into the high $60s in mid-2023 and again in the low $70s last December. With WTI now trading at $87, the White House <a href="https://thehill.com/policy/energy-environment/4574215-biden-buyback-oil-stockpile/">cancelled an intended purchase</a> of 3MM barrels.</p>
<p><img alt="spr_gridlines.jpg" src="https://www.benzinga.com/files/images/2024/April/18/spr_gridlines.jpg" style="height:355px; width:624px" /></p>
<p>The last time the SPR was this low, the population of the US was 35% lower.</p>
<p>DKI Takeaway:&nbsp; The SPR was intended to be insurance against geopolitical volatility, not a political piggy bank. Currently, we have a war in the Middle East and another involving Russia, two huge oil-producing regions. Additional issues related to Red Sea shipping and restrictions on exports of Russian oil are making energy transportation more challenging. With inflation and the economy as the top issues for US voters, the White House is going to do all they can to try to keep the price of gas low heading into the November election. This strategy leaves the US more exposed to both international problems and a potential fall hurricane. We&rsquo;re hoping this doesn&rsquo;t lead to a national security issue.</p>
<ul>
<li><strong>Global Oil Inventories Are Declining:</strong></li>
</ul>
<p>Tracy Shuchart @chigrl notes: The US Energy Information Administration, after <a href="https://www.eia.gov/outlooks/steo/report/global_oil.php">forecasting</a>&nbsp;global inventories to remain unchanged this quarter, now predicts they&rsquo;ll fall by 900,000 barrels a day. That&rsquo;s the equivalent to the production from&nbsp;<a href="https://www.iea.org/countries/oman/oil">Oman</a>. The supply squeeze comes as demand is ramping up. US refiners are preparing to boost fuel production for the summer, when millions of Americans take to the roads and gasoline consumption peaks.&nbsp;Gasoline stockpiles&nbsp;on the populous East Coast are tightening and&nbsp;<a href="https://www.bloomberg.com/news/articles/2024-04-01/asia-s-factories-paint-picture-of-uneven-recovery-in-march">manufacturing activity</a>&nbsp;in the US and China is also signaling a boost in fuel use. In Asia, refining margins are around 50% higher than the five-year seasonal average, suggesting healthy demand. (from Bloomberg)</p>
<p><img alt="global_oil_inventories_are_declining.jpg" src="https://www.benzinga.com/files/images/2024/April/18/global_oil_inventories_are_declining.jpg" style="height:362px; width:624px" /></p>
<p>Lower inventories lead to higher prices.</p>
<p>DKI Takeaway:&nbsp; This means higher for longer unless OPEC+ decides to discontinue its voluntary cuts of over 1M bpd at the June 1, 2024 meeting. Saudi Arabia is shouldering the burden of most of these cuts, so ultimately, it&rsquo;s their decision. Both the EIA Short term Energy Outlook and the OPEC monthly that were released this week anticipate the US to add ~360K bpd in 2024. We disagree with this due to reductions in rigs, DUC (drilled but uncompleted), new wells, and higher GOR (gas to oil ratio). However, with OPEC expecting US production to grow, this gives Saudi Arabia incentive to maintain current production levels in order to keep prices elevated to fund their aggressive agenda to turn Saudi Arabia into a world-renowned tourist destination, and other large projects.</p>
<ul>
<li>
<p><strong>The Problems in Commercial Real Estate Are Getting Worse:</strong></p>
</li>
</ul>
<p>We&rsquo;ve been reporting on problems in the commercial real estate sector for the past few editions of The Five Things. More people moving away from big cities combined with employees&rsquo; insistence on working from home/anywhere are putting pressure on the commercial office space market. One way landlords are hiding the problem is with giveaways. The scheme works like this:&nbsp; With vacancies high, tenants have leverage to insist on lower rent. In order to avoid reporting rent decreases which would reduce the implied value of the building, the landlord will insist on maintaining the same listed rent while offering the tenant free months or rebates for expensive renovations. The effective rent is lower, but the discount is hidden.</p>
<p><img alt="office_building_rent_-_wsj_graph_.jpg" src="https://www.benzinga.com/files/images/2024/April/18/office_building_rent_-_wsj_graph_.jpg" style="height:450px; width:367px" /></p>
<p>Chart from the <a href="https://www.wsj.com/real-estate/commercial/office-landlords-use-cash-gifts-loans-to-inflate-building-values-92faae2a">Wall Street Journal</a>.</p>
<p>DKI Takeaway:&nbsp; DKI has spent the past three years writing about how government statistics like the CPI, GDP, and the recent employment reports have been faked, revised when few were looking, or just lies. Unfortunately, misleading and fake data isn&rsquo;t limited to the government. When real estate companies report rents that are high only due to undisclosed giveaways, it&rsquo;s technically legal, technically not a lie, and deliberately designed to mislead investors. The commercial real estate market is worse than the official statistics indicate, and we applaud the Wall Street Journal for covering this almost-fraud in detail.</p>
<p>Information contained in this report, and in each of its reports, is believed by Deep Knowledge Investing (&ldquo;DKI&rdquo;) to be accurate and/or derived from sources which it believes to be reliable; however, such information is presented without warranty of any kind, whether express or implied.&nbsp; DKI makes no representation as to the completeness, timeliness, accuracy or soundness of the information and opinions contained therein or regarding any results that may be obtained from their use.&nbsp;The information and opinions contained in this report and in each of our reports and all other DKI Services shall not obligate DKI to provide updated or similar information in the future, except to the extent it is required by law to do so.&nbsp;</p>
<p>The information we provide in this and in each of our reports, is publicly available. This report and each of our reports are neither an offer nor a solicitation to buy or sell securities. All expressions of opinion in this and in each of our reports are precisely that. Our opinions are subject to change, which DKI may not convey. DKI, affiliates of DKI or its principal or others associated with DKI may have, taken or sold, or may in the future take or sell positions in securities of companies about which we write, without disclosing any such transactions.</p>
<p>None of the information we provide or the opinions we express, including those in this report, or in any of our reports, are advice of any kind, including, without limitation, advice that investment in a company&rsquo;s securities is prudent or suitable for any investor. In making any investment decision, each investor should consult with and rely on his or its own investigation, due diligence and the recommendations of investment professionals whom the investor has engaged for that purpose.&nbsp;</p>
<p>In no event shall DKI be liable, based on this or any of its reports, or on any information or opinions DKI expresses or provides for any losses or damages of any kind or nature including, without limitation, costs, liabilities, trading losses, expenses (including, without limitation, attorneys&rsquo; fees), direct, indirect, punitive, incidental, special or consequential damages.</p>


Economics

General

5 Things To Know In Investing This Week - The Inflation And Oil Issue

<p>RBC Capital  analyst Walter Spracklin   maintains CSX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>) with a Sector Perform and lowers the price target from $37 to $36.</p>


Price Target

Analyst Ratings

RBC Capital Maintains Sector Perform on CSX, Lowers Price Target to $36

Asset Sales

Bentley Systems Is Exploring Options That Include A Sale After Attracting Interest From Potential Suitors, Sources Say

<p><strong>Primerica, Inc. </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRI#NYSE">PRI</a>) shares have turned lower Thursday after the <strong>Bear Cave</strong> issued a fresh <a href="https://www.benzinga.com/quote/PRI">short report on the stock</a>.</p>
<p><strong>What Happened:</strong> Short-selling firm the Bear Cave has targeted <a href="https://www.benzinga.com/quote/PRI">Primerica stock</a> in a new bearish report claiming the company&#8217;s highest-producing agents are engaged in misleading, false, or deceptive behavior.</p>
<p>The short seller noted Primerica explicitly states that its business model, which involved deploying life insurance-licensed sales representatives to provide financial products and services to middle-income households, was &#8220;not a pyramid scheme.&#8221;</p>
<p>&#8220;The Bear Cave sees things differently,&#8221; the short seller said. </p>
<p>Benzinga reached out to Primerica for comment, but has not yet received a response. </p>
<p>The Bear Cave said it reviewed extensive evidence that suggested Primerica&#8217;s agents were engaging in deceptive conduct including a recorded Zoom presentation that appeared to suggest an internal investigation was ongoing. Other evidence included a recruiting script for new agents that appeared to deliberately obfuscate their association with Primerica, agent presentations that emphasize recruiting and more. </p>
<p>&#8220;One text message recruiting script for Primerica agents, obtained by The Bear Cave through online searches, even appears to conceal the role of Primerica and instead instructs recruits to say the company is &#8216;PFS Inc,&#8217; potentially so friends and family won't find the voluminous online criticism of Primerica,&#8221; the short seller said.</p>
<p><em>See Also: <a href="https://www.benzinga.com/general/biotech/24/04/38223087/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">Benzinga&#8217;s &#8216;Stock Whisper&#8217; Index: 5 Stocks Investors Secretly Monitor But Don&#8217;t Talk About Yet</a></em></p>
<p>Beyond aggressive recruiting, the Bear Cave claimed some top agents also appear concerned about cultural integrity issues at the company, noting that one million dollar earner asked questions about dishonest business practices in a recorded <a href="https://www.benzinga.com/quote/ZM">Zoom</a> call from 2023.</p>
<p>The Bear Cave also said it obtained complaints against Primerica through a public records request filed with the Florida Attorney General's Office.&nbsp;&nbsp;</p>
<p>&#8220;Primerica customers aren't the only ones complaining. Across blogs, <a href="https://substack.com/redirect/2a7730d9-86d5-4177-a884-b8d982688faf?j=eyJ1IjoiajNodzMifQ.sIewgBW7xiJjZmaK0rxt5pEYk6b3GjQ0U-w2sm2TViM">Reddit</a>, and YouTube many ex-Primerica agents are sharing their bad Primerica experiences. And on Glassdoor many of the reviews are no better,&#8221; the Bear Cave said.</p>
<p>Primerica had a market cap of approximately $7.34 billion as of Wednesday&#8217;s close.</p>
<p><strong>PRI Price Action:</strong> <a href="https://www.benzinga.com/quote/PRI">Primerica shares</a> were down 8.94% at $192.72 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.</p>
<p><em>This illustration was generated using artificial intelligence via Midjourney.</em></p>


Short Sellers

Insurance

Short Seller Targets Primerica Stock Claiming Agents Are Engaged In Deceptive Behavior, Shares Sink

Meta Platforms Says Llama 3 Trained On Both Text And Images, Though Current Versions Will Only Output Text For Now; Meta AI Virtual Assistant Will Be Updated To Include New Models And Given Standalone Website; Releases Two Early Versions Of Next-Gen Llama 3 Large Language Model; Company Struck Partnership With Google To Include Its Search Results In Assistant's Responses

Barnes Group shares are trading higher after DA Davidson upgraded the stock from Neutral to Buy and raised its price target from $35 to $45.

<p>In the preceding three months, 4 analysts have released ratings for Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $77.25, along with a high estimate of $87.00 and a low estimate of $65.00. Experiencing a 11.54% decline, the current average is now lower than the previous average price target of $87.33. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713456109_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>A comprehensive examination of how financial experts perceive Bio-Techne is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Justin Bowers</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$82.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Daniel Arias</td>
<td>Stifel</td>
<td>Announces</td>
<td>Hold</td>
<td>$65.00</td>
<td>-</td>
</tr>
<tr>
<td>Jacob Johnson</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$87.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$75.00</td>
<td>$85.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Bio-Techne. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Bio-Techne compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Bio-Techne's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Bio-Techne's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TECH/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Bio-Techne analyst ratings.</strong></a></p>
<h2>About Bio-Techne</h2>
<p>Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.</p>
<h3>Bio-Techne's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Bio-Techne showcased positive performance, achieving a revenue growth rate of <strong>0.37%</strong> as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Bio-Techne's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>10.07%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Bio-Techne's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>1.39%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.0%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.28</strong>, Bio-Techne adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TECH

Navigating 4 Analyst Ratings For Bio-Techne

<p>Stephens &amp; Co.  analyst Matt Breese   maintains Fulton Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULT#NASDAQ">FULT</a>) with a Equal-Weight and lowers the price target from $16 to $15.5.</p>


FULT

Stephens & Co. Maintains Equal-Weight on Fulton Financial, Lowers Price Target to $15.5

<p>Ratings for Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) were provided by 12 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $69.58, a high estimate of $90.00, and a low estimate of $45.00. This upward trend is apparent, with the current average reflecting a 34.98% increase from the previous average price target of $51.55.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713456063_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Carvana. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rajat Gupta</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$80.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Montani</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$77.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Michael Montani</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$78.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Michael Montani</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$75.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>John Colantuoni</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$85.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$90.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Adam Jonas</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$45.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$80.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Underperform</td>
<td>$45.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Seth Basham</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Seth Basham</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$50.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Carvana. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Carvana compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Carvana's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Carvana's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CVNA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Carvana analyst ratings.</strong></a></p>
<h2>About Carvana</h2>
<p>Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage. The foundation of the business is retail vehicle unit sales. This drives the majority of the revenue and allows the company to capture additional revenue streams associated with financing, VSCs, auto insurance and GAP waiver coverage, as well as trade-in vehicles.</p>
<h3>Unraveling the Financial Story of Carvana</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Carvana faced challenges, resulting in a decline of approximately <strong>-14.56%</strong> in revenue growth as of 31 December, 2023. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-4.7%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Carvana's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-39.18%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-1.62%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Carvana's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>27.6</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CVNA

In-Depth Examination Of 12 Analyst Recommendations For Carvana

<p>Ratings for AES (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>) were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $22.25, a high estimate of $25.00, and a low estimate of $19.00. Witnessing a positive shift, the current average has risen by 3.01% from the previous average price target of $21.60.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713456055_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>A comprehensive examination of how financial experts perceive AES is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthony Crowdell</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Buy</td>
<td>$21.00</td>
<td>-</td>
</tr>
<tr>
<td>Shelby Tucker</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$22.00</td>
<td>-</td>
</tr>
<tr>
<td>Gregg Orrill</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Gary Hovis</td>
<td>Argus Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$25.00</td>
<td>-</td>
</tr>
<tr>
<td>Stephen Byrd</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Stephen Byrd</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Stephen Byrd</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Stephen Byrd</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$21.00</td>
<td>$18.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AES. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of AES compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of AES's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of AES's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/AES/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on AES analyst ratings.</strong></a></p>
<h2>Get to Know AES Better</h2>
<p>AES is a global power company. Its generation portfolio as of year-end 2023 totals over 35 gigawatts, including renewable energy (53%), gas (27%), coal (18%), and oil (2%). AES has majority ownership and operates six electric utilities distributing power to more than 2.5 million customers.</p>
<h3>A Deep Dive into AES's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Negative Revenue Trend:</strong> Examining AES's financials over 3 months reveals challenges. As of 31 December, 2023, the company experienced a decline of approximately <strong>-3.01%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Utilities sector.</p>
<p><strong>Net Margin:</strong> AES's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-3.17%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> AES's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-5.24%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> AES's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-0.21%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>16.29</strong>, caution is advised due to increased financial risk.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Beyond The Numbers: 8 Analysts Discuss AES Stock

<p>Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) has outperformed the market over the past 10 years by 6.65% on an annualized basis producing an average annual return of 17.02%. Currently, Danaher has a market capitalization of $175.79 billion. </p>
<p><strong>Buying $100 In DHR:</strong> If an investor had bought $100 of DHR stock 10 years ago, it would be worth <strong>$480.41</strong> today based on a price of $237.38 for DHR at the time of writing.</p>
<h3>Danaher's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713456050_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


If You Invested $100 In This Stock 10 Years Ago, You Would Have $500 Today

<p>Analysts' ratings for Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) over the last quarter vary from bullish to bearish, as provided by 19 analysts.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $137.47, with a high estimate of $160.00 and a low estimate of $105.00. Marking an increase of 10.08%, the current average surpasses the previous average price target of $124.88. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713456045_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>A comprehensive examination of how financial experts perceive Oracle is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Ader</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$150.00</td>
<td>-</td>
</tr>
<tr>
<td>Kash Rangan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$130.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Stephen Bersey</td>
<td>HSBC</td>
<td>Raises</td>
<td>Buy</td>
<td>$155.00</td>
<td>$144.00</td>
</tr>
<tr>
<td>Kirk Materne</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Derrick Wood</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$142.00</td>
<td>$126.00</td>
</tr>
<tr>
<td>Kash Rangan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$130.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Siti Panigrahi</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$160.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$120.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Announces</td>
<td>Neutral</td>
<td>$105.00</td>
<td>-</td>
</tr>
<tr>
<td>Karl Keirstead</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$115.00</td>
<td>$106.00</td>
</tr>
<tr>
<td>Mark Moerdler</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$159.00</td>
<td>$147.00</td>
</tr>
<tr>
<td>Brad Sills</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$144.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Mark Murphy</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$105.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$147.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$120.00</td>
<td>$111.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Oracle. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Oracle compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Oracle's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Oracle's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ORCL/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Oracle analyst ratings.</strong></a></p>
<h2>Delving into Oracle's Background</h2>
<p>Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.</p>
<h3>Oracle: Financial Performance Dissected</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Oracle showcased positive performance, achieving a revenue growth rate of <strong>7.11%</strong> as of 29 February, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.</p>
<p><strong>Net Margin:</strong> Oracle's net margin excels beyond industry benchmarks, reaching <strong>18.08%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Oracle's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>50.61%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Oracle's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>1.77%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Oracle's debt-to-equity ratio surpasses industry norms, standing at <strong>15.65</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ORCL

19 Analysts Have This To Say About Oracle

<p>Alamos Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGI#NYSE">AGI</a>) has outperformed the market over the past 5 years by 15.36% on an annualized basis producing an average annual return of 26.78%. Currently, Alamos Gold has a market capitalization of $6.02 billion. </p>
<p><strong>Buying $100 In AGI:</strong> If an investor had bought $100 of AGI stock 5 years ago, it would be worth <strong>$325.43</strong> today based on a price of $15.14 for AGI at the time of writing.</p>
<h3>Alamos Gold's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713456044_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$100 Invested In This Stock 5 Years Ago Would Be Worth $300 Today

<p>In the preceding three months, 4 analysts have released ratings for Nicolet Bankshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIC#NYSE">NIC</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $87.12, a high estimate of $92.00, and a low estimate of $82.50. A negative shift in sentiment is evident as analysts have decreased the average price target by 1.37%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713456037_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Nicolet Bankshares. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Terry McEvoy</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$88.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Damon Delmonte</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$86.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Terry McEvoy</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$92.00</td>
<td>-</td>
</tr>
<tr>
<td>Nathan Race</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$82.50</td>
<td>$88.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Nicolet Bankshares. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Nicolet Bankshares compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Nicolet Bankshares's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>To gain a panoramic view of Nicolet Bankshares's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/NIC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Nicolet Bankshares analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Get to Know Nicolet Bankshares Better</h2>
<p>Nicolet Bankshares Inc is a United States-based bank holding company's principal business is banking, consisting of lending and deposit gathering, as well as ancillary banking-related products and services, to businesses and individuals of the communities it serves, and the operational support to deliver, fund and manage. It offers a variety of loans, deposits, and related services to business customers especially small and medium-sized businesses and professional concerns, business deposit products, cash management services, international banking services, business loans, lines of credit, commercial real estate financing, construction loans, agricultural real estate or production loans, and letters of credit, as well as retirement plan services.</p>
<h3>Key Indicators: Nicolet Bankshares's Financial Health</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Revenue Growth:</strong> Nicolet Bankshares's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of <strong>9.91%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> Nicolet Bankshares's net margin excels beyond industry benchmarks, reaching <strong>33.54%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Nicolet Bankshares's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>3.05%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Nicolet Bankshares's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>0.36%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.16</strong>, Nicolet Bankshares adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Expert Outlook: Nicolet Bankshares Through The Eyes Of 4 Analysts

<p>Across the recent three months, 5 analysts have shared their insights on GXO Logistics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GXO#NYSE">GXO</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $65.6, with a high estimate of $75.00 and a low estimate of $50.00. Experiencing a 6.95% decline, the current average is now lower than the previous average price target of $70.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713456027_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive GXO Logistics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rick Paterson</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$74.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Brian Ossenbeck</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Hugo Watkins</td>
<td>Exane BNP Paribas</td>
<td>Announces</td>
<td>Neutral</td>
<td>$50.00</td>
<td>-</td>
</tr>
<tr>
<td>Bascome Majors</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$75.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Christian Wetherbee</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$64.00</td>
<td>$66.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to GXO Logistics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of GXO Logistics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of GXO Logistics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into GXO Logistics's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/GXO/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on GXO Logistics analyst ratings.</strong></a></p>
<h2>Delving into GXO Logistics's Background</h2>
<p>GXO Logistics Inc is a contract logistics company. Its revenue is diversified across numerous verticals and customers, including many multinational corporations. It provides warehousing and distribution, order fulfillment, e-commerce, reverse logistics, and other supply chain services differentiated by its ability to deliver technology-enabled, customized solutions at scale. Geographically, it generates revenue from the United Kingdom, the United States, the Netherlands, France, Spain, Italy, and other countries, and derives the majority of its revenue from the United Kingdom.</p>
<h3>Financial Milestones: GXO Logistics's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> GXO Logistics displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately <strong>4.99%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Industrials sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> GXO Logistics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>2.82%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> GXO Logistics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>2.56%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>0.78%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> GXO Logistics's debt-to-equity ratio is below the industry average at <strong>1.4</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


5 Analysts Assess GXO Logistics: What You Need To Know

<p><strong>Longeveron's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NYSE">LGVN</a>) short percent of float has fallen 83.09% since its last report. The company recently reported that it has <strong>28 thousand shares sold short</strong>, which is 2.79% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 1.0 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Longeveron Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713456026_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Longeveron has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing Longeveron's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Longeveron's peer group average for short interest as a percentage of float is 2.52%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Ideas

LGVN

Peering Into Longeveron's Recent Short Interest

<p><strong>DuPont de Nemours's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) short percent of float has fallen 10.7% since its last report. The company recently reported that it has <strong>7.10 million shares sold short</strong>, which is 1.92% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 3.9 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>DuPont de Nemours Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713456020_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for DuPont de Nemours has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing DuPont de Nemours's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, DuPont de Nemours's peer group average for short interest as a percentage of float is 4.10%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Peering Into DuPont de Nemours's Recent Short Interest

<p><strong>Air Products &amp; Chemicals's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APD#NYSE">APD</a>) short percent of float has fallen 17.46% since its last report. The company recently reported that it has <strong>2.30 million shares sold short</strong>, which is 1.04% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 1.58 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Air Products &amp; Chemicals Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713456015_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Air Products &amp; Chemicals has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing Air Products &amp; Chemicals's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Air Products &amp; Chemicals's peer group average for short interest as a percentage of float is 3.25%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


(APD) - Analyzing Air Products & Chemicals's Short Interest

Ensysce Biosciences falls on exercise of warrants for $4.7M gross proceeds

Ensysce Biosciences (ENSC) has released an update. Ensysce Biosciences, Inc. has struck a deal with warrant holders to exercise existing warrants f...

Ensysce Biosciences Secures Funding and Expands Shareholder Value

Ensysce Biosciences reports Q4 results

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Ensysce Biosciences</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/ensc-stock-quote/"><strong>ENSC</strong></a></span>) just reported results for the fourth quarter of 2023.</p><ul><li>Ensysce Biosciences reported earnings per share of -$1.13. This was below the analyst estimate for EPS of -87 cents.</li><li>The company reported revenue of $515,032.</li><li>This was 32.06% better than the analyst estimate for revenue of $390,000.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/03/ensc-stock-earnings-ensysce-biosciences-for-q4-of-2023/">ENSC Stock Earnings: Ensysce Biosciences Misses EPS, Beats Revenue for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

ENSC Stock Earnings: Ensysce Biosciences Misses EPS, Beats Revenue for Q4 2023

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Fisker </strong>(NYSE:<a href="https://investorplace.com/stock-quotes/fsr-stock-quote/"><strong>FSR</strong></a>) stock is moving on Monday after the electric vehicle (EV) company announced that it has secured an <a href="https://investors.fiskerinc.com/news/news-details/2024/Fisker-Announces-Receipt-of-Financing-Commitment-of-Up-to-150-Million-and-Provides-Business-Update/default.aspx">additional $150 million in funding</a>.</p>



<p>According to a press release from Fisker, the company&rsquo;s new funding comes from the holder of its 2025-dated convertible notes. It&rsquo;s also worth noting that this funding is being split into four tranches.</p>



<p>Fisker also mentions that this funding is only available if it meets certain conditions. Chief among these is the filing of the company&rsquo;s Form 10-K for 2023.</p>



<p>Investors will keep in mind that Fisker still has inventory from 2023 on hand. Combined with what has been produced in 2024, it has an excess inventory of over $200 million. The company is pausing production for six weeks starting today to align its inventory.</p>



<p>It&rsquo;s also worth mentioning that Fisker is still in talks with a large automaker for an investment. This has it hoping for funding to develop an EV platform with the manufacturer.</p>



<h2>How This Affects FSR Stock Today</h2>



<p>Despite news of the additional financing, shares of FSR stock are still falling on Monday. This has the stock down 12% this morning.</p>



<p>That drop for FSR stock comes alongside some 136 million shares changing hands. That&rsquo;s a massive surge in trading volume compared to the company&rsquo;s average of about 67 million shares.</p>



<p>Investors searching for more of the latest stock market stories are in luck!</p>



<p>We have all of the hottest stock market news ready to go on Monday! A few examples include what has shares of <strong>Nio</strong>&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/nio-stock-quote/"><strong>NIO</strong></a>), <strong>Xpeng&nbsp;</strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/xpev-stock-quote/"><strong>XPEV</strong></a>) and <strong>Ensysce Biosciences</strong>&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ensc-stock-quote/"><strong>ENSC</strong></a>) stock moving today. All of that information is ready to go at the links below!</p>



<h2>More Monday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/03/nio-stock-ceo-william-li-says-second-gen-nio-phone-is-underway/">NIO Stock: CEO William Li Says Second-Gen Nio Phone Is Underway</a></li>



<li><a href="https://investorplace.com/2024/03/xpev-stock-alert-xpeng-pops-on-news-of-cheaper-ev-brand/">XPEV Stock Alert: Xpeng Pops on News of Cheaper EV Brand</a></li>



<li><a href="https://investorplace.com/earning-results/2024/03/ensc-stock-earnings-ensysce-biosciences-for-q4-of-2023/">ENSC Stock Earnings: Ensysce Biosciences Misses EPS, Beats Revenue for Q4 2023</a></li>
</ul><p><em>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT793992">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793990">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793999">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/2024/03/fsr-stock-the-150-million-reason-fisker-shares-are-moving-today/">FSR Stock: The $150 Million Reason Fisker Shares Are Moving Today</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

FSR Stock: The $150 Million Reason Fisker Shares Are Moving Today

The market has been high on Ensysce Biosciences Inc (ENSC)  stock recently. ENSC gets a Bullish score from InvestorsObserver Stock Sentiment Indicator. Ensysce Biosciences Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ENSC!See Full ENSC ReportWhat is Stock Sentime

How Will the Market React to Ensysce Biosciences Inc (ENSC) Stock Getting a Bullish Rating

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Fisker </strong>(NYSE:<a href="https://investorplace.com/stock-quotes/fsr-stock-quote/"><strong>FSR</strong></a>) stock is moving on Monday after the electric vehicle (EV) company announced that it has secured an <a href="https://investors.fiskerinc.com/news/news-details/2024/Fisker-Announces-Receipt-of-Financing-Commitment-of-Up-to-150-Million-and-Provides-Business-Update/default.aspx">additional $150 million in funding</a>.</p>



<p>According to a press release from Fisker, the company&rsquo;s new funding comes from the holder of its 2025-dated convertible notes. It&rsquo;s also worth noting that this funding is being split into four tranches.</p>



<p>Fisker also mentions that this funding is only available if it meets certain conditions. Chief among these is the filing of the company&rsquo;s Form 10-K for 2023.</p>



<p>Investors will keep in mind that Fisker still has inventory from 2023 on hand. Combined with what has been produced in 2024, it has an excess inventory of over $200 million. The company is pausing production for six weeks starting today to align its inventory.</p>



<p>It&rsquo;s also worth mentioning that Fisker is still in talks with a large automaker for an investment. This has it hoping for funding to develop an EV platform with the manufacturer.</p>



<h2>How This Affects FSR Stock Today</h2>



<p>Despite news of the additional financing, shares of FSR stock are still falling on Monday. This has the stock down 12% this morning.</p>



<p>That drop for FSR stock comes alongside some 136 million shares changing hands. That&rsquo;s a massive surge in trading volume compared to the company&rsquo;s average of about 67 million shares.</p>



<p>Investors searching for more of the latest stock market stories are in luck!</p>



<p>We have all of the hottest stock market news ready to go on Monday! A few examples include what has shares of <strong>Nio</strong>&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/nio-stock-quote/"><strong>NIO</strong></a>), <strong>Xpeng&nbsp;</strong>(NYSE:<a href="https://investorplace.com/stock-quotes/xpev-stock-quote/"><strong>XPEV</strong></a>) and <strong>Ensysce Biosciences</strong>&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ensc-stock-quote/"><strong>ENSC</strong></a>) stock moving today. All of that information is ready to go at the links below!</p>



<h2>More Monday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/03/nio-stock-ceo-william-li-says-second-gen-nio-phone-is-underway/">NIO Stock: CEO William Li Says Second-Gen Nio Phone Is Underway</a></li>



<li><a href="https://investorplace.com/2024/03/xpev-stock-alert-xpeng-pops-on-news-of-cheaper-ev-brand/">XPEV Stock Alert: Xpeng Pops on News of Cheaper EV Brand</a></li>



<li><a href="https://investorplace.com/earning-results/2024/03/ensc-stock-earnings-ensysce-biosciences-for-q4-of-2023/">ENSC Stock Earnings: Ensysce Biosciences Misses EPS, Beats Revenue for Q4 2023</a></li>
</ul><p><em><strong>On Penny Stocks and Low-Volume Stocks:&#8239;</strong>With only the rarest exceptions,&nbsp;InvestorPlace&nbsp;does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s&nbsp;writers disclose this fact and warn readers of the risks.</em>&nbsp;</p>



<p><em><strong>Read More:&#8239;</strong></em><a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/"><em>Penny Stocks &mdash;&nbsp;How to Profit Without Getting Scammed</em></a></p>



<p><em>On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/2024/03/fsr-stock-the-150-million-reason-fisker-shares-are-moving-today/">FSR Stock: The $150 Million Reason Fisker Shares Are Moving Today</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Ensysce Biosciences</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/ensc-stock-quote/"><strong>ENSC</strong></a></span>) just reported results for the fourth quarter of 2023.</p><ul><li>Ensysce Biosciences reported earnings per share of -$1.13. This was below the analyst estimate for EPS of -87 cents.</li><li>The company reported revenue of $515,032.</li><li>This was 32.06% better than the analyst estimate for revenue of $390,000.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT793992">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793990">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793999">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/03/ensc-stock-earnings-ensysce-biosciences-for-q4-of-2023/">ENSC Stock Earnings: Ensysce Biosciences Misses EPS, Beats Revenue for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

XPEV

Biotech Soars On FDA Announcement

Press Releases

Ensysce Biosciences to Present Groundbreaking Oral Overdose Protection for Opioids at the 5th Annual NIH HEAL Meeting

Biotech

Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain

Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual Conference

Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds

Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript

Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection

Ensysce Biosciences Receives Positive Nasdaq Listing Determination

Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results

Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference